Medication info

Traglitin Combi Tablet 2.5/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Daewon Pharmaceutical Co., Ltd.
Appearance
Bright pink, film-coated, biconvex oval tablets
Packaging
30 tablets/box [6 tablets/PTP x 5]
Approval status
Active

MFDS item code 201902340 · Approved 2019.04.16

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous pharmacological treatment for diabetes whose blood glucose is not adequately controlled with monotherapy, the initial dose of this medicine is 2.5/500 mg, 1 tablet twice daily; the dose may be increased to 2.5/1000 mg, 1 tablet twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., patients taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from concomitant therapy with linagliptin and metformin: Patients switching from concomitant therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with concomitant metformin and sulfonylurea therapy: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be needed to reduce the risk of hypoglycemia (see Precautions for Use 3. Patients Requiring Caution). 5. Patients whose blood glucose is not adequately controlled with concomitant insulin and metformin therapy: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered with insulin, a reduction in the insulin dose may be needed to reduce the risk of hypoglycemia (see Precautions for Use 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in a type 2 diabetes treatment regimen may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment Because this medicine contains metformin, it should not be administered to patients with impaired hepatic function (see Precautions for Use 2. Contraindications).

Ingredients

Manufacturer
Daewon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication helps patients with type 2 diabetes to control their blood sugar levels by using linagliptin and metformin together. It complements basic treatment methods such as dietary control and exercise to help manage blood sugar more effectively. This contributes to reducing the risk of complications related to diabetes and maintaining health, and is used to keep patients' blood sugar levels stable.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous pharmacological treatment for diabetes whose blood glucose is not adequately controlled with monotherapy, the initial dose of this medicine is 2.5/500 mg, 1 tablet twice daily; the dose may be increased to 2.5/1000 mg, 1 tablet twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., patients taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from concomitant therapy with linagliptin and metformin: Patients switching from concomitant therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with concomitant metformin and sulfonylurea therapy: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be needed to reduce the risk of hypoglycemia (see Precautions for Use 3. Patients Requiring Caution). 5. Patients whose blood glucose is not adequately controlled with concomitant insulin and metformin therapy: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered with insulin, a reduction in the insulin dose may be needed to reduce the risk of hypoglycemia (see Precautions for Use 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in a type 2 diabetes treatment regimen may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment Because this medicine contains metformin, it should not be administered to patients with impaired hepatic function (see Precautions for Use 2. Contraindications).

Precautions

This medication can cause a serious side effect called lactic acidosis, and should not be administered to patients with impaired kidney function or liver damage. Patients who are allergic to the active ingredients or components of this medication, those with type 1 diabetes, and patients with acute myocardial infarction or severe heart failure should also not take this medication. Particular caution is required when using this medication in patients with slightly impaired kidney function, the elderly, those with unstable heart function, patients receiving iodinated contrast media, and those scheduled for surgery. This medication can cause hypoglycemia, so when taken with insulin or sulfonylurea agents, blood sugar changes should be closely monitored. Rare side effects such as acute pancreatitis or bullous pemphigoid causing blisters may occur, so if abdominal pain or skin abnormalities arise during use, consult a doctor immediately. The metformin component may lower vitamin B12 levels, so regular checks for vitamin B12 deficiency are necessary during long-term use. This medication is not recommended for women who are pregnant or breastfeeding, and should be discussed with a doctor if pregnancy is planned. Safety and efficacy have not been sufficiently established for children under 10 years of age or for adolescents aged 10 to 17, and is not recommended for these groups. Elderly patients may have reduced kidney function, so it is advisable to regularly monitor kidney function and to start at the minimum dose. Alcohol consumption may increase the risk of lactic acidosis, so it should be avoided, and when used in conjunction with other medications, the possibility of interactions should be considered under the advice of a physician. Additionally, this medication should be stored in a cool, dry place away from moisture and out of reach of children.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • taste disorder
  • cough
  • decreased appetite
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
Show 120 more
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • blistering dermatitis
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficient vitamin B12
  • constipation
  • upper abdominal pain
  • enterocolitis
  • bowel obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorder
  • Alzheimer’s dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • colorectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage kidney disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • anxiety
  • mood disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • chest discomfort
  • weakness
  • pain
  • nosebleed
  • oropharyngeal pain
  • phonation disorder
  • epistaxis
  • hearing loss
  • erectile dysfunction
  • goiter
  • anemia
  • pruritus
  • delirium
  • nocturia
  • dermatitis
  • hypertension
  • benign prostatic hyperplasia
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • increased blood triglycerides
  • decreased hemoglobin
  • increased blood potassium
  • increased blood creatinine
  • increased blood creatine phosphokinase
  • increased blood glucose
  • increased blood creatinine
  • facial edema
  • hyperthermia
  • back pain
  • osteoarthritis
  • limb pain
  • rotator cuff syndrome
  • dizziness
  • sensory loss
  • headache
  • drowsiness
  • diabetic neuropathy
  • drowsiness
  • anxiety
  • depression
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and moisture. It is also important to keep it at room temperature between 1°C and 30°C to maintain its effectiveness.

Appearance and packaging

Appearance

Bright pink, film-coated, biconvex oval tablets

Package unit

30 tablets/box [6 tablets/PTP x 5]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.